GARS1 and Alzheimer disease: Altogether, these findings indicate that treatment with artesunate might support the slow tonic inhibition mediated by GlyRs in the hippocampus in such a way as to restore functionally relevant intrinsic homeostatic paradigms altered in AD pathogenesis.